ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess â„¢) for frown ...
1,10 Results demonstrate the long-term safety of repeated RelabotulinumtoxinA injections, consistent with the safety profile observed in the phase III READY-1, -2 and -3 clinical trials.1,4,9,11 ...
X4 Pharmaceuticals (XFOR) announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mavorixafor, an oral ...
Mavorixafor was generally well tolerated as a monotherapy and in combination with G-CSF, with no drug-related serious adverse ...
The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.
Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...
The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...
The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...
Stockhead on MSN14d
ASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trialPAR made substantial progress in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis (OA) with ...
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback